title: Effect of genetic polymorphism of UCP2-866 G/A on repaglinide response in Chinese patients with type 2 diabetes.
abstract: The aim of the present study was to evaluate the impact of the UCP2-866 G/A polymorphism on the efficacy of repaglinide in treating patients with diabetes mellitus type 2 (T2DM). 370 patients with T2DM and 166 healthy volunteers were enrolled to identify UCP2-866 G/A genotypes. 16 patients with GG genotype, 14 with GA genotype and 11 with AA genotype of UCP2-866 G/A underwent an 8-week repaglinide treatment regimen. There were no differences in allele frequency of UCP2-866 G/A between T2DM patients and control subjects. The patient with AA genotype of UCP2-866 G/A had higher levels of fasting plasma glucose (FPG), 30-min and 2-h postload plasma glucose, glycated haemoglobin (HbA1c), and lower concentrations of 30-min and 2-h postload plasma insulin, homeostasis model assessment of beta cell function (HOMA-beta), deltaI30/deltaG30 compared with GG genotype. After repaglinide treatment for 8 consecutive weeks, we found that A allele carriers of UCP2 in the T2DM patients had smaller decrease in FPG (P < 0.05) and HbA1c (P < 0.05), and smaller increase in 30-min postload plasma insulin (P < 0.01) compared with GG genotypes. We demonstrated that UCP2-866 G/A polymorphism is associated with the therapeutic efficacy of repaglinide in Chinese T2DM patients.
authors.affiliation: Department of Endocrinology, Xiang-Ya Hospital, Changsha, Hunan, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Wang
authors.forename: Yan-Mei
authors.initials: YM
authors.lastname: Se
authors.forename: Zhao-Qian
authors.initials: ZQ
authors.lastname: Liu
authors.forename: Ming-Xiang
authors.initials: MX
authors.lastname: Lei
authors.lastname: Hao-BoYang
authors.forename: Zhi-Xiang
authors.initials: ZX
authors.lastname: Sun
authors.forename: Sheng-Dan
authors.initials: SD
authors.lastname: Nie
authors.forename: Xiao-min
authors.initials: XM
authors.lastname: Zeng
authors.forename: Jing
authors.initials: J
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D000483:Alleles; D044466:Asian People / Q000235:genetics; D001786:Blood Glucose / Q000378:metabolism; D002219:Carbamates / Q000494:pharmacology*; D017931:DNA Primers; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000097:blood; D050417:Insulin-Secreting Cells / Q000502:physiology; D007473:Ion Channels / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D024101:Mitochondrial Proteins / Q000235:genetics*; D010186:Pancreatic Function Tests; D010880:Piperidines / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D000071246:Uncoupling Protein 2
chemical_list: D001786:Blood Glucose; D002219:Carbamates; D017931:DNA Primers; D007004:Hypoglycemic Agents; D007328:Insulin; D007473:Ion Channels; D024101:Mitochondrial Proteins; D010880:Piperidines; C000604389:UCP2 protein, human; D000071246:Uncoupling Protein 2; C072379:repaglinide